30 September 2023 in Neurotoxicity Research
Despite sustained efforts to treat neurodegenerative diseases, little is known at the molecular level to understand and generate novel therapeutic approaches for these malignancies. Therefore, it is not surprising that neurogenerative diseases are among the leading causes of death in the aged population. Neurons require sophisticated cellular mechanisms to maintain proper protein homeostasis. These cells are generally sensitive to loss of gene expression control at the post-transcriptional level. Post-translational control responds to signals that can arise from intracellular processes or environmental factors that can be regulated through RNA-binding proteins. These proteins recognize RNA through one or more RNA-binding domains and form ribonucleoproteins that are critically involved in the regulation of post-transcriptional processes from splicing to the regulation of association of the translation machinery allowing a relatively rapid and precise modulation of the transcriptome. Neurotoxicity is the result of the biological, chemical, or physical interaction of agents with an adverse effect on the structure and function of the central nervous system. The disruption of the proper levels or function of RBPs in neurons and glial cells triggers neurotoxic events that are linked to neurodegenerative diseases such as spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), fragile X syndrome (FXS), and frontotemporal dementia (FTD) among many others. The connection between RBPs and neurodegenerative diseases opens a new landscape for potentially novel therapeutic targets for the intervention of these neurodegenerative pathologies. In this contribution, a summary of the recent findings of the molecular mechanisms involved in the plausible role of RBPs in RNA processing in neurodegenerative disease is discussed.
1 January 2025 in International Journal of Food Science
The Agave cupreata leaves are the main crop residues generated by the mezcal industry. It is known that agave leaves are potential sources of antibacterial and anti‐inflammatory compounds that could be used in the pharmaceutical industry. Therefore, the valorization of crop residues and maximal utilization of this material are of major research interest in the development of environmentally and sustainably produced products. In this study, the aqueous extract was microencapsulated (MCAC) from Agave cupreata leaves in order to evaluate its physicochemical properties, stability, and antibacterial and antiulcerogenic activity. The results showed that MCAC exhibited a spherical shape, concavities, and a rough surface. The phytochemical profile showed that MCAC presented flavonoids, terpenes, and saponins. Optimal storage conditions at 35°C for MCAC were determined from adsorption isotherms. The integrity of MCAC was observed up to a water activity of 0.436. The results of the antibacterial activity demonstrated a growth inhibitory effect of PAC and MCAC on Gram‐negative bacteria at a concentration of 32 mg mL −1 . In animal experiments, compared with the negative control (absolute ethanol), MCAC and PAC powders exerted a protective effect against ethanol‐induced gastric ulcers, with protection rates of 34.45% and 92.24%, respectively. The results suggest that the powder obtained in the present study may be useful as a food additive and/or as an ingredient of pharmaceutical drugs.